SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB Biotherapeutics announced the pricing of an $85 million public offering consisting of 19.3 million shares at $3.85 per share and pre-funded warrants. The company plans to use proceeds to fund development of SAB-142, its clinical-stage candidate for type 1 diabetes, through ongoing Phase 2b trials and related activities. The offering is expected to close on March 19, 2026.

03/17/2026, 10:46 PM • Benzinga

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB Biotherapeutics (Nasdaq: SABS) announced a public offering of 19.3 million shares at $3.85 per share and 2.75 million pre-funded warrants, expected to raise approximately $85 million in gross proceeds. The company plans to use the funds to advance development of SAB-142, its lead candidate for type 1 diabetes, through ongoing clinical trials and related activities.

03/17/2026, 10:46 PM • GlobeNewswire

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics announced that its management team will participate in two investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company is developing SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes treatment.

02/04/2026, 9:00 AM • GlobeNewswire

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two decades of experience in biopharmaceutical development and clinical strategy. Both appointments are intended to support the company's advancement of SAB-142, its lead candidate for Type 1 Diabetes treatment, through clinical development and potential commercialization.

01/07/2026, 8:00 AM • GlobeNewswire

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

SAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.

12/17/2025, 8:00 AM • GlobeNewswire

SILQFi Launches Omni Following Acquisition of OXO

SILQFi has launched Omni, a new financial platform for small businesses, after acquiring OXO. The platform integrates point-of-sale, procurement, payments, and credit access to streamline merchant workflows and improve capital access in Saudi Arabia.

09/16/2025, 5:31 AM • Benzinga